Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carbon-Mercaptooctadecane/Carboxylated Multi-walled Carbon Nanotubes Composite Based Genosensor for Detection of Bacterial Meningitis.

Indian journal of microbiology·2014
Same author

nspA gene as a specific genetic marker for detection of Neisseria meningitidis causing bacterial meningitis.

Indian journal of biochemistry & biophysics·2014
Same author

Quick diagnosis of human brain meningitis using omp85 gene amplicon as a genetic marker.

Indian journal of microbiology·2014
Same author

Cognitive impairment and diabetes.

Recent patents on endocrine, metabolic & immune drug discovery·2013
Same author

Engineered polymer-supported synthesis of 3'-carboxyalkyl-modified oligonucleotides and their applications in the construction of biochips for diagnosis of the diseases.

Bioconjugate chemistry·2012
Same author

Future targeted disease modifying drugs for Alzheimer's disease.

Recent patents on CNS drug discovery·2010

Related Experiment Video

Updated: May 10, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Zolpidem in progressive supranuclear palsy.

Sandip K Dash1

  • 1Department of Neurology, Apollo Hospitals Dhaka, Basundhara R/A, Dhaka 1229, Bangladesh.

Case Reports in Neurological Medicine
|June 14, 2013
PubMed
Summary
This summary is machine-generated.

Zolpidem, a GABA agonist, showed potential in improving motor and cognitive symptoms in a Progressive Supranuclear Palsy (PSP) patient. Further trials are needed to confirm zolpidem

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Related Experiment Videos

Last Updated: May 10, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Area of Science:

  • Neuroscience
  • Neurology
  • Pharmacology

Background:

  • Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder with no effective treatments.
  • GABA neurotransmission deficits in the striatum and globus pallidus are implicated in PSP symptoms.
  • Zolpidem acts as a GABA agonist at the BZ1 benzodiazepine subreceptor.

Purpose of the Study:

  • To describe a case of Progressive Supranuclear Palsy (PSP) treated with zolpidem.
  • To investigate the potential therapeutic effects of zolpidem on PSP symptoms.
  • To discuss the possible mechanisms of action for zolpidem in PSP.

Main Methods:

  • A case study of a nondiabetic, normotensive patient with Progressive Supranuclear Palsy (PSP).
  • Administration of zolpidem therapy.
  • Observation and discussion of symptom changes and potential mechanisms.

Main Results:

  • The patient exhibited improvements in swallowing, speech, and gaze paresis after zolpidem treatment.
  • The study discusses potential mechanisms underlying these observed improvements.

Conclusions:

  • Zolpidem therapy demonstrated potential benefits for specific symptoms in a PSP patient.
  • Larger clinical trials are necessary to validate the efficacy of zolpidem for Progressive Supranuclear Palsy (PSP).